EUVIMEDEUVIMED entdecken
Crossref

Prevalence, Distribution, and Characteristics Associated With Possession of Buprenorphine Waivers Among Infectious Diseases Physicians in the United States

Ayako Wendy Fujita iD, Nora Loughry, DeLante E Moore, Andrea E Carter, Sophia A Hussen, Hannah Cooper, Jonathan A Colasanti, Anandi N Sheth

Clinical Infectious Diseases · 2023

DOI: 10.1093/cid/ciac909 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2023. Verfasst von Ayako Wendy Fujita und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Emory University Department of Medicine, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: Buprenorphine, Physicians, Opioid-Related Disorders, Communicable Diseases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: National Center for Advancing Translational Sciences, National Institute of Allergy and Infectious Diseases, National Institute on Drug Abuse.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Persons with opioid use disorder (OUD) may present with infectious complications from injection drug use; thus, infectious diseases (ID) physicians are uniquely positioned to treat OUD. Buprenorphine is safe and effective for OUD but remains underutilized. The prevalence and geographic distribution of ID physicians who are waivered to prescribe buprenorphine are unknown.

Methods

This cross-sectional study merged data from several publicly available datasets from 1 November 2021 to 15 January 2022. Our primary outcome was the proportion of ID physicians possessing buprenorphine waivers in the United States. We identified individual- and county-level characteristics associated with buprenorphine waiver possession. We then used geospatial analysis to determine the geographic distribution of waivered ID physicians.

Results

We identified 6372 ID physicians in the United States, among whom 170 (2.7%) possessed waivers. Most ID physicians (97.3%) practiced in metropolitan counties. In our multivariable analysis, ID physicians had lower odds of having a waiver for every 10-year increase since graduating medical school (OR: .79; 95% CI: .68–.91). ID physicians practicing in counties with a higher proportion of uninsured residents had lower odds of having a waiver (OR: .75; 95% CI: .62–.90). Among counties with ≥1 ID physician (n = 729), only 11.2% had ≥1 waivered ID physician.

Conclusions

We found an extremely low prevalence and skewed geographic distribution of ID physicians with buprenorphine waivers. Our findings suggest an urgent need to increase the workforce of ID physicians waivered to prescribe buprenorphine and a call for increased integration of OUD education into ID training and continuing medical education.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BuprenorphinePhysiciansOpioid-Related DisordersCommunicable DiseasesHumansUnited StatesOpiate Substitution TreatmentCross-Sectional StudiesPrevalencePractice Patterns, Physicians'

Stichwörter der Autor:innen

X-waiverbuprenorphineopioid use disorder

Substanzen

Buprenorphine

Autor:innen und Institutionen

  • Division of Infectious Diseases, Emory University Department of Medicine, Atlanta, Georgia, USA.
  • Division of General Internal Medicine, Emory University Department of Medicine, Atlanta, Georgia, USA.
  • Department of Biostatistics, Emory University Department of Medicine, Rollins School of Public Health, Atlanta, Georgia, USA.
  • Division of General Internal Medicine, University of Pittsburgh Department of Medicine, Pittsburgh, Pennsylvania, USA.
  • Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA.
  • Department of Behavioral, Social, and Health Education Services, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA.

ORCID-Profile: Ayako Wendy Fujita

Förderung

  • National Center for Advancing Translational Sciences
  • National Institute of Allergy and Infectious Diseases
  • National Institute on Drug Abuse

Zitieren

APA

Fujita, A. W., Loughry, N., Moore, D. E., Carter, A. E., Hussen, S. A., Cooper, H., Colasanti, J. A., & Sheth, A. N. (2023). Prevalence, Distribution, and Characteristics Associated With Possession of Buprenorphine Waivers Among Infectious Diseases Physicians in the United States. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciac909

Vancouver

Fujita AW, Loughry N, Moore DE, Carter AE, Hussen SA, Cooper H, et al. Prevalence, Distribution, and Characteristics Associated With Possession of Buprenorphine Waivers Among Infectious Diseases Physicians in the United States. Clinical Infectious Diseases. 2023. doi:10.1093/cid/ciac909

BibTeX
@article{Fujita2023,
  author = {Fujita, Ayako Wendy and Loughry, Nora and Moore, DeLante E and Carter, Andrea E and Hussen, Sophia A and Cooper, Hannah and Colasanti, Jonathan A and Sheth, Anandi N},
  title = {Prevalence, Distribution, and Characteristics Associated With Possession of Buprenorphine Waivers Among Infectious Diseases Physicians in the United States},
  journal = {Clinical Infectious Diseases},
  year = {2023},
  doi = {10.1093/cid/ciac909}
}
Kostenlos starten →